Before the Bell
$
151.16
Change
+0.15 +0.51%
Volume
Volume 19
May 16, 2022, 8:27 a.m.
Quotes are delayed by 20 min
Previous close
$ 150.40
$ 150.40
Change
+6.33 +4.39%
Day low
Day high
$146.32
$152.01

52 week low
52 week high
$137.21
$327.32

Market cap
$8.34B
Average volume
547,174
P/E ratio
59.57
Rev. per Employee
$396,381
EPS
2.52
Dividend
N/A
Div yield
N/A
Ex dividend date
N/A
MarketWatch News on RGEN
-
Repligen stock price target cut to $230 from $320 at Stifel Nicolaus
- Tomi Kilgore
-
Repligen stock price target raised to $335 from $255 at KeyBanc Capital
- Tomi Kilgore
-
How a 53-Year-Old Growth Fund Takes the Long View
- Barron's Online
-
Repligen started at overweight with $241 stock price target at KeyBanc Capital
- Tomi Kilgore
-
Hunting for Stock Market Bargains? It’s Time to Head to Europe and Japan
- Barron's Online
-
Small-Cap ‘Darlings’ Are Perking Up in 2020
- Barron's Online
-
These 6 stocks in the S&P 1500 have more than doubled in 12 months
- Philip van Doorn
-
Charting a Fed-fueled bullish reversal, S&P 500 nails the breakdown point
- Michael Ashbaugh
-
Repligen started at overweight with $42 stock price target at J.P. Morgan
- Tomi Kilgore
-
Repligen stock fair value estimate raised to $47 from $42 at Janney
- Tomi Kilgore
-
Repligen agrees to buy Spectrum in a cash-and-stock deal valued at $359 mln
- Tomi Kilgore
-
Repligen's stock halted for news pending
- Tomi Kilgore
-
Repligen's stock was inactive premarket prior to trading halt
- Tomi Kilgore
-
- Barron's Online
-
Why Danaher’s Purchase of Pall Means More M&A is on the Way
- Barrons Blogs
- Loading more headlines...
Analyst Ratings
-
Benzinga's Top Upgrades, Downgrades For December 8, 2017
- Benzinga.com
-
Benzinga's Top Upgrades, Downgrades For December 5, 2017
- Benzinga.com
-
- Benzinga.com
Other News on RGEN
-
- Seeking Alpha
-
LRT Capital Management March 2022 Investor Update
- Seeking Alpha
-
Why Repligen Is Up More Than 10% Today
- Motley Fool
-
Repligen Q1 2022 Earnings Preview
- Seeking Alpha
-
Notable earnings before Wednesday's open
- Seeking Alpha
-
2 Reasons to Buy Repligen, and 1 Reason to Sell
- Motley Fool
-
2 Top Biotech Stocks to Buy for the Long Haul
- Motley Fool
- Loading more headlines...
Press Releases on RGEN
-
Repligen to Report First Quarter 2022 Financial Results
- GlobeNewswire
-
Regeneron Drug Could be Less Effective vs. Omicron
- Baystreet.ca
-
Repligen Corporation to Present at Upcoming Investor Conferences
- GlobeNewswire
-
IMPULSE DYNAMICS APPOINTS FIVE NEW BOARD MEMBERS
- GlobeNewswire
-
Repligen Releases Inaugural Sustainability Report
- GlobeNewswire
-
Repligen to Report Third Quarter 2021 Financial Results
- GlobeNewswire
-
Repligen Announces Agreement to Acquire Avitide Inc.
- GlobeNewswire
- Loading more headlines...
Rates »
National averages from Bankrate.com
National averages from Bankrate.com
National averages from Bankrate.com